Virtus LifeSci Biotech Clinical Trials ETF Rating $45.89 -0.40 (-0.86%) As of 12:35 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Ratings Stock AnalysisChartDividendHoldingsOwnershipRatings Virtus LifeSci Biotech Clinical Trials ETF Aggregate Rating and Price Target (2026)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.BBC Aggregate RatingModerate Buy 2.77Holdings in BBC have an aggregate rating of Moderate Buy based on 295 analyst ratings issued in the past year covering 25 companies (28.1% of the portfolio).BBC Aggregate Price Target$46.291.78% UpsideHigh Prediction$46.29Average Prediction$46.29Low Prediction$46.29Holdings in BBC have an aggregate price target of $46.29 and a range of $46.29 to $46.29 covering 25 companies (28.1% of the portfolio).BBC Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy3 Buy rating(s)Moderate Buy21 Moderate Buy rating(s)Hold1 Hold rating(s)Reduce0 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by Virtus LifeSci Biotech Clinical Trials ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 25 BBC Holdings ExportWeight In ETFCompanyShare PriceConsensus RatingConsensus Price TargetPossible UpsideNumber of RatingsMarketRank™Indicator(s)ViewRatings1.68%ABCLAbCellera Biologics$13.98-4.2%Moderate Buy$13.38 -4.3%91.2254 of 5 starsNews CoverageAnalyst Forecast1.50%AMLXAmylyx Pharmaceuticals$28.30-2.7%Buy$38.86 37.3%103.5084 of 5 starsPositive News1.48%TRAXFirst Tracks Biotherapeutics$35.21-0.7%Moderate Buy$65.17 85.1%143.1257 of 5 starsNews CoveragePositive NewsAnalyst Forecast1.41%XNCRXencor$25.05+0.4%Moderate Buy$34.00 35.7%111.9901 of 5 starsAnalyst Forecast1.21%FDMT4D Molecular Therapeutics$14.34+0.2%Moderate Buy$29.00 102.3%122.814 of 5 starsAnalyst Forecast1.16%MBXMBX Biosciences$57.99-1.1%Moderate Buy$77.00 32.8%132.6485 of 5 starsNews CoverageAnalyst Forecast1.15%ORICOric Pharmaceuticals$12.97-3.7%Moderate Buy$20.18 55.6%152.0934 of 5 starsInsider Trade1.11%QUREuniQure$24.73+2.3%Moderate Buy$58.18 135.3%162.8785 of 5 starsTrending NewsAnalyst ForecastOptions Volume1.09%DFTXDefinium Therapeutics$38.17+0.3%Buy$64.88 70.0%213.0308 of 5 starsInsider Trade1.09%ANLAdlai Nortye$15.85-0.9%Moderate Buy$29.50 86.1%71.9238 of 5 starsNews CoverageInsider Trade1.09%SGPSpyglass Pharma$26.28+1.1%Moderate Buy$44.00 67.5%82.4756 of 5 starsNews CoveragePositive News1.07%ZBIOZenas BioPharma$28.89+7.1%Moderate Buy$46.71 61.7%92.2654 of 5 starsNews CoverageAnalyst Forecast1.07%MNPRMonopar Therapeutics$78.88-1.0%Moderate Buy$121.36 53.9%122.8967 of 5 starsNews CoverageInsider Trade1.05%SLSSELLAS Life Sciences Group$11.79-4.2%Hold$10.00 -15.2%30.3286 of 5 starsNews Coverage1.04%VKTXViking Therapeutics$31.37-3.8%Moderate Buy$99.67 217.7%122.9794 of 5 starsGap Down1.04%REPLReplimune Group$13.32+0.6%Moderate Buy$12.00 -9.9%101.4284 of 5 stars1.01%NRIXNurix Therapeutics$23.82+0.4%Moderate Buy$34.21 43.7%152.3715 of 5 starsUpcoming Earnings1.01%ACHVAchieve Life Sciences$7.76-4.1%Buy$15.50 99.8%93.2002 of 5 starsNews CoverageAnalyst ForecastGap Down1.01%IMMXImmix Biopharma$10.24-1.5%Moderate Buy$24.14 135.8%93.0441 of 5 starsNews CoveragePositive NewsAnalyst Forecast0.99%LBRXLB Pharmaceuticals$38.07-0.8%Moderate Buy$49.63 30.4%102.5241 of 5 starsPositive News0.98%PVLAPalvella Therapeutics$136.76-0.8%Moderate Buy$209.14 52.9%152.2365 of 5 stars0.96%KYMRKymera Therapeutics$116.10+3.9%Moderate Buy$133.21 14.7%261.635 of 5 stars0.96%VORVor Biopharma$18.66-2.2%Moderate Buy$41.71 123.5%101.9064 of 5 stars0.95%GENBGenerate Biomedicines$14.26-5.0%Moderate Buy$26.40 85.1%82.645 of 5 stars0.94%CADLCandel Therapeutics$10.30-1.3%Moderate Buy$20.14 95.5%113.1735 of 5 starsNews CoverageGap Up This page (NYSEARCA:BBC) was last updated on 10/1/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Virtus LifeSci Biotech Clinical Trials ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Virtus LifeSci Biotech Clinical Trials ETF With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
